Pancreatic Cancer Research

ResearcherTel Aviv UniversityActive in the last 2 years

Eric Van Cutsem

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0002-6372-1230; OpenAlex author ID A5090645179. Sources: ClinicalTrials.gov.

Their work

Papers
37 (first author 2, last author 5)
Trials
1 (principal investigator on 1)
Grants
0
Labs led
2
Collaborators
162
Papers, trials and grants by year

2011: 2 papers · 2012: 1 paper · 2013: 1 paper · 2014: 1 paper, 1 trial · 2015: none · 2016: none · 2017: 1 paper · 2018: 4 papers · 2019: 4 papers · 2020: 4 papers · 2021: 2 papers · 2022: 2 papers · 2023: 4 papers · 2024: 1 paper · 2025: 6 papers · 2026: 4 papers

Papers 37

  1. The European Multidisciplinary Evidence-Based Guideline on Pancreatic Cancer: Methodological Protocol. Co-author DOI 10.1002/gin2.70074↗
  2. NALIRIFOX versus nab-paclitaxel and gemcitabine in older patients with treatment-naive metastatic pancreatic cancer: a subgroup analysis of the pivotal NAPOLI … Co-author DOI 10.1016/j.esmoop.2025.106043↗
  3. Response to Letter to the Editor: 'NALIRIFOX versus nab-paclitaxel and gemcitabine in older patients with treatment-naive metastatic pancreatic cancer: a subgr… Co-author DOI 10.1016/j.esmoop.2026.108307↗
  4. The OligoPanc project: an interdisciplinary expert consensus statement on oligometastatic pancreatic cancer. Co-author DOI 10.1016/s1470-2045(25)00714-4↗
  5. Health-related quality of life and performance status with NALIRIFOX versus nab-paclitaxel + gemcitabine in treatment-naive patients with metastatic pancreatic… Co-author DOI 10.1016/j.esmoop.2025.105534↗
  6. Progression-free survival for unresectable non-metastatic locally advanced pancreatic cancer after surgical microwave ablation plus durvalumab and tremelimumab… Co-author DOI 10.1038/s43856-025-01186-x↗
  7. A plain language summary of NALIRIFOX compared with nab-paclitaxel and gemcitabine for patients with metastatic pancreatic cancer (NAPOLI 3). Co-author DOI 10.1080/14796694.2025.2458458↗
  8. Tumor Treating Fields With Gemcitabine and Nab-Paclitaxel for Locally Advanced Pancreatic Adenocarcinoma: Randomized, Open-Label, Pivotal Phase III PANOVA-3 St… Co-author DOI 10.1200/jco-25-00746↗
  9. TRYBECA-1: A Randomized Phase III Study of Eryaspase Combined With Chemotherapy Versus Chemotherapy as Second-Line Treatment in Patients With Advanced Pancreat… Co-author DOI 10.1200/jco-25-00872↗
  10. CA19-9 as a Dynamic Biomarker for Continuous Monitoring of Therapeutic Efficacy in Pancreatic Adenocarcinoma. Co-author DOI 10.3390/cancers17243902↗
  11. Efficacy and Safety of the Anti-IL1RAP Antibody Nadunolimab (CAN04) in Combination with Gemcitabine and Nab-Paclitaxel in Patients with Advanced/Metastatic Pan… Co-author DOI 10.1158/1078-0432.ccr-24-0645↗
  12. Napabucasin plus nab-paclitaxel with gemcitabine versus nab-paclitaxel with gemcitabine in previously untreated metastatic pancreatic adenocarcinoma: an adapti… Last author DOI 10.1016/j.eclinm.2023.101897↗
  13. NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): a randomised, open-lab… Co-author DOI 10.1016/s0140-6736(23)01366-1↗
  14. Human pancreatic cancer patients with Epithelial-to-Mesenchymal Transition and an aggressive phenotype show a disturbed balance in Protein Phosphatase Type 2A … Co-author DOI 10.1186/s12967-023-04145-z↗
  15. Adjuvant nab-Paclitaxel + Gemcitabine in Resected Pancreatic Ductal Adenocarcinoma: Results From a Randomized, Open-Label, Phase III Trial. Co-author DOI 10.1200/jco.22.01134↗
  16. Expert opinion on management of pancreatic exocrine insufficiency in pancreatic cancer. Co-author DOI 10.1016/j.esmoop.2022.100386↗
  17. Overall Survival Results From the POLO Trial: A Phase III Study of Active Maintenance Olaparib Versus Placebo for Germline BRCA-Mutated Metastatic Pancreatic C… Co-author DOI 10.1200/jco.21.01604↗
  18. Ibrutinib in combination with nab-paclitaxel and gemcitabine for first-line treatment of patients with metastatic pancreatic adenocarcinoma: phase III RESOLVE … Co-author DOI 10.1016/j.annonc.2021.01.070↗
  19. Randomized Phase III Study of FOLFOX Alone or With Pegilodecakin as Second-Line Therapy in Patients With Metastatic Pancreatic Cancer That Progressed After Gem… Co-author DOI 10.1200/jco.20.02232↗
  20. Molecular Targeting of a BRAF Mutation in Pancreatic Ductal Adenocarcinoma: Case Report and Literature Review. Last author DOI 10.1007/s11523-020-00727-9↗
  21. Gemcitabine Recruits M2-Type Tumor-Associated Macrophages into the Stroma of Pancreatic Cancer. Co-author DOI 10.1016/j.tranon.2020.01.004↗
  22. Geographic and Ethnic Heterogeneity of Germline BRCA1 or BRCA2 Mutation Prevalence Among Patients With Metastatic Pancreatic Cancer Screened for Entry Into the… Co-author DOI 10.1200/jco.19.01890↗
  23. Randomized Phase III Trial of Pegvorhyaluronidase Alfa With Nab-Paclitaxel Plus Gemcitabine for Patients With Hyaluronan-High Metastatic Pancreatic Adenocarcin… Co-author DOI 10.1200/jco.20.00590↗
  24. Optimizing the management of locally advanced pancreatic cancer with a focus on induction chemotherapy: Expert opinion based on a review of current evidence. Last author DOI 10.1016/j.ctrv.2019.05.007↗
  25. Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer. Co-author DOI 10.1056/nejmoa1903387↗
  26. Health-related quality of life in patients with a germline BRCA mutation and metastatic pancreatic cancer receiving maintenance olaparib. Co-author DOI 10.1093/annonc/mdz406↗
  27. Gemcitabine induces Epithelial-to-Mesenchymal Transition in patient-derived pancreatic ductal adenocarcinoma xenografts. Co-author PMID 30899378↗
  28. Phase I/II trial of pimasertib plus gemcitabine in patients with metastatic pancreatic cancer. Co-author DOI 10.1002/ijc.31603↗
  29. Ruxolitinib + capecitabine in advanced/metastatic pancreatic cancer after disease progression/intolerance to first-line therapy: JANUS 1 and 2 randomized phase… First author DOI 10.1007/s10637-018-0580-2↗
  30. Consensus statement on mandatory measurements in pancreatic cancer trials (COMM-PACT) for systemic treatment of unresectable disease. Co-author DOI 10.1016/s1470-2045(18)30098-6↗
  31. Scleroderma-like cutaneous lesions during treatment with paclitaxel and gemcitabine in a patient with pancreatic adenocarcinoma. Review of literature. Co-author DOI 10.1111/ijd.14067↗
  32. Phase 2 placebo-controlled, double-blind trial of dasatinib added to gemcitabine for patients with locally-advanced pancreatic cancer. First author DOI 10.1093/annonc/mdw607↗
  33. Dose escalation to rash for erlotinib plus gemcitabine for metastatic pancreatic cancer: the phase II RACHEL study. Co-author DOI 10.1038/bjc.2014.494↗
  34. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. Co-author DOI 10.1056/nejmoa1304369↗
  35. Pancreatic adenocarcinoma: ESMO-ESDO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Co-author DOI 10.1093/annonc/mds224↗
  36. Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: a double-blind randomised phase 3 study. Last author DOI 10.1016/s1470-2045(11)70004-3↗
  37. Pancreatic cancer treatment and research: an international expert panel discussion. Last author DOI 10.1093/annonc/mdq545↗

Trials 1

  1. Quality of Life in Locally Advanced or Metastatic Pancreatic Cancer Treated With Gemcitabine and Nab-paclitaxel Principal investigator NCT02106884↗

Closest collaborators

The 25 strongest of 162 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Teresa Mercade Macarulla · 17 shared papers, 2018–2026 · strength 2.09
  2. Eileen Mary O'Reilly · 10 shared papers, 2018–2026 · strength 1.38
  3. Roberto Pazo-Cid · 6 shared papers, 2023–2026 · strength 1.16
  4. Tanios Bekaii‐Saab · 6 shared papers, 2023–2026 · strength 1.14
  5. Zev A. Wainberg · 5 shared papers, 2023–2026 · strength 0.99
  6. Andrew Scott Paulson · 5 shared papers, 2023–2026 · strength 0.99
  7. Davide Melisi · 5 shared papers, 2023–2026 · strength 0.99
  8. Richard A Hubner · 5 shared papers, 2023–2026 · strength 0.99
  9. Shubham Pant · 5 shared papers, 2023–2026 · strength 0.99
  10. Michele Reni · 9 shared papers, 2013–2023 · strength 0.78
  11. Pascal R. Hammel · 8 shared papers, 2018–2025 · strength 0.77
  12. Chris Verslype · 7 shared papers, 2018–2023 · strength 0.68
  13. Christelle de la Fouchardière · 4 shared papers, 2020–2025 · strength 0.62
  14. Do‐Youn Oh · 6 shared papers, 2019–2023 · strength 0.59
  15. Sreenivasa Rao Chandana · 3 shared papers, 2023–2025 · strength 0.54
  16. Thorsten Oliver Goetze · 3 shared papers, 2023–2025 · strength 0.54
  17. Igor Kišš · 3 shared papers, 2023–2025 · strength 0.54
  18. Dirk Arnold · 5 shared papers, 2019–2024 · strength 0.54
  19. Baki Topal · 3 shared papers, 2020–2025 · strength 0.53
  20. Joon Oh Park · 5 shared papers, 2019–2022 · strength 0.48
  21. Hassan A. Hatoum · 2 shared papers, 2026 · strength 0.46
  22. Vincent M. Chung · 2 shared papers, 2026 · strength 0.46
  23. Jos F. van Pelt · 3 shared papers, 2019–2023 · strength 0.40
  24. Hedy Lee Kindler · 5 shared papers, 2011–2022 · strength 0.38
  25. Jean‐Luc Van Laethem · 3 shared papers, 2018–2025 · strength 0.38

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.